全文获取类型
收费全文 | 97105篇 |
免费 | 45932篇 |
国内免费 | 256篇 |
专业分类
耳鼻咽喉 | 1705篇 |
儿科学 | 4722篇 |
妇产科学 | 1068篇 |
基础医学 | 17465篇 |
口腔科学 | 5679篇 |
临床医学 | 14022篇 |
内科学 | 29876篇 |
皮肤病学 | 7762篇 |
神经病学 | 15384篇 |
特种医学 | 3143篇 |
外科学 | 18477篇 |
综合类 | 63篇 |
一般理论 | 26篇 |
预防医学 | 4965篇 |
眼科学 | 1721篇 |
药学 | 6927篇 |
中国医学 | 1052篇 |
肿瘤学 | 9236篇 |
出版年
2023年 | 283篇 |
2022年 | 250篇 |
2021年 | 2115篇 |
2020年 | 5592篇 |
2019年 | 11563篇 |
2018年 | 10976篇 |
2017年 | 12089篇 |
2016年 | 12879篇 |
2015年 | 12736篇 |
2014年 | 12915篇 |
2013年 | 13643篇 |
2012年 | 6162篇 |
2011年 | 5979篇 |
2010年 | 10036篇 |
2009年 | 6337篇 |
2008年 | 3757篇 |
2007年 | 2527篇 |
2006年 | 2472篇 |
2005年 | 2249篇 |
2004年 | 2161篇 |
2003年 | 1821篇 |
2002年 | 1734篇 |
2001年 | 635篇 |
2000年 | 473篇 |
1999年 | 183篇 |
1998年 | 181篇 |
1997年 | 150篇 |
1996年 | 153篇 |
1995年 | 158篇 |
1994年 | 135篇 |
1993年 | 121篇 |
1992年 | 100篇 |
1991年 | 65篇 |
1990年 | 71篇 |
1989年 | 55篇 |
1988年 | 41篇 |
1987年 | 37篇 |
1986年 | 45篇 |
1985年 | 37篇 |
1984年 | 38篇 |
1983年 | 34篇 |
1982年 | 49篇 |
1981年 | 30篇 |
1980年 | 28篇 |
1979年 | 23篇 |
1978年 | 17篇 |
1977年 | 10篇 |
1976年 | 12篇 |
1975年 | 15篇 |
1974年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Ruscitti Piero Di Cola Ilenia Berardicurti Onorina Conforti Alessandro Iacono Daniela Pantano Ilenia Rozza Gelsomina Rossi Silvia De Stefano Ludovico Balduzzi Silvia Vitale Antonio Caso Francesco Costa Luisa Prete Marcella Navarini Luca Atzeni Fabiola Guggino Giuliana Perosa Federico Cantarini Luca Frediani Bruno Montecucco Carlomaurizio Ciccia Francesco Giacomelli Roberto Cipriani Paola 《Clinical rheumatology》2022,41(11):3597-3597
Clinical Rheumatology - 相似文献
2.
Cifuentes-Faura Javier Di Francesco Renaud 《The European journal of health economics》2022,23(4):559-563
The European Journal of Health Economics - 相似文献
3.
Naveen Pemmaraju MD Jacqueline S. Garcia MD Andrew Perkins MBBS PhD Jason G. Harb PhD Andrew J. Souers PhD Michael E. Werner PhD Christopher M. Brown PhD Francesco Passamonti MD 《Cancer》2023,129(22):3535-3545
Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and symptom relief but demonstrate limited ability to lead to a durable disease modification. There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-XL) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment. 相似文献
4.
Foc Emanuele Fornari Chiara Arsuffi Stefania Vetrano Maria Chiara Calza Stefano Renzetti Stefano Copeta Silvia Berruti Alfredo Castelli Francesco Compostella Silvia Quiros-Roldan Eugenia 《AIDS and behavior》2022,26(9):2920-2930
AIDS and Behavior - People living with chronic disease (PLWCD) are the frailest category, both for the risk of severe COVID-19 illness and for the impact on the care continuum. Aim of this study... 相似文献
5.
6.
Darren Ming‐Chun Poon 《Asia-Pacific Journal of Clinical Oncology》2020,16(Z3):18-23
For advanced and metastatic urothelial carcinomas (UCs), platinum (preferably cisplatin)‐based chemotherapy has been the standard treatment for many years. However, many patients are ineligible for cisplatin‐based chemotherapy because of poor performance status and/or other age‐related conditions. At the other end of the spectrum, patients with localized non‐muscle–invasive bladder cancer who are unresponsive to intravesical Bacillus Calmette‐Guérin (BCG) treatment often face radical cystectomy as the only option. In recent years, the application of immunotherapy in the form of immune‐checkpoint inhibitors has provided viable alternatives in the second‐line postplatinum and first‐line cisplatin‐ineligible settings. Recent and ongoing clinical trials are also assessing the safety and efficacy of immunotherapy for neoadjuvant and adjuvant uses before/after cystectomy, for BCG‐unresponsive cases, and for combination treatments that include the newer indoleamine 2,3‐dioxygenase‐1 inhibitors and/or BCG. This review summarizes recent developments in immunotherapy for UCs. 相似文献
7.
8.
9.
10.
Javad Sharifi‐Rad Shahira M. Ezzat Mahitab H. El Bishbishy Dima Mnayer Farukh Sharopov Ceyda S. Kl Monica Neagu Carolina Constantin Mehdi Sharifi‐Rad Maria Atanassova Silvana Nicola Giuseppe Pignata Bahare Salehi Patrick V. T. Fokou Natlia Martins 《Phytotherapy research : PTR》2020,34(7):1474-1518
Rosmarinus species are aromatic plants that mainly grow in the Mediterranean region. They are widely used in folk medicine, food, and flavor industries and represent a valuable source of biologically active compounds (e.g., terpenoids, flavonoids, and phenolic acids). The extraction of rosemary essential oil is being done using three main methods: carbon dioxide supercritical extraction, steam distillation, and hydrodistillation. Furthermore, interesting antioxidant, antibacterial, antifungal, antileishmanial, anthelmintic, anticancer, anti‐inflammatory, antidepressant, and antiamnesic effects have also been broadly recognized for rosemary plant extracts. Thus the present review summarized data on economically important Rosmarinus officinalis species, including isolation, extraction techniques, chemical composition, pharmaceutical, and food applications. 相似文献